| SAREPTA THERAPEUTICS |
| USA |
| Gesundheit |
| US8036071004 / A1J1BH |
| AB3A (Frankfurt) / SRPT (NASDAQ) |
| FRA:AB3A, ETR:AB3A, AB3A:GR, NASDAQ:SRPT |
| - |
| https://www.sarepta.com/ |
|
Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for rare diseases, with a strong emphasis on genetic and neuromuscular disorders. The company’s current portfolio includes appro..
>Volltext.. |
| 1459.65 Mio. EUR |
| 1684.96 Mio. EUR |
| 1713.52 Mio. EUR |
| -0.3 Mio. EUR |
| -230.95 Mio. EUR |
| -2.28 EUR |
| 907.69 Mio. EUR |
| 495.7 Mio. EUR |
| 81.54 Mio. EUR |
| 1.57 |
| -17.94% |
| -373.59% |
| - |
| - |
| - |
| - |
| SAREPTA, AVI BIOPHARMA |
| 07.08.26 |
|
||||
|
||||
|
||||
|